Sleep apnoea syndrome in 2011: Current concepts and future directions

European Respiratory Review

Volumn 20, Issue 121, 2011, Pages 134-146

  Levy P ^a   Tamisier, R ^a   Minville, C ^a   Launois, S ^a   Pepin J L ^a  

^a University Grenoble Alpes   (France)

Author keywords

[No Author keywords available]

Indexed keywords

REACTIVE OXYGEN METABOLITE; VALSARTAN;

AGE DISTRIBUTION; ARTICLE; ATHEROSCLEROSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ELDERLY CARE; HEART FAILURE; HUMAN; HYPERTENSION; HYPOXIA; INFLAMMATION; INTERMETHOD COMPARISON; LUNG COLLAPSE; METABOLIC DISORDER; NONHUMAN; OBESITY HYPOVENTILATION SYNDROME; OXIDATIVE STRESS; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; RISK FACTOR; SLEEP APNEA SYNDROME; STRATEGIC PLANNING; THERAPY EFFECT; TREATMENT DURATION;

ANIMALS; ANOXIA; BIOMECHANICS; CARDIOVASCULAR DISEASES; HUMANS; METABOLIC DISEASES; PHARYNX; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 80052527239     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00003111     Document Type: Article

References (188)

1. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnoea: a population health perspective. Am J Respir Crit Care Med 2002; 165: 1217-1239.
2. White DP. Pathogenesis of obstructive and central sleep apnea. Am J Respir Crit Care Med 2005; 172: 1363-1370.
3. Boyd JH, Petrof BJ, Hamid Q, et al. Upper airway muscle inflammation and denervation changes in obstructive sleep apnea. Am J Respir Crit Care Med 2004; 170: 541-546.
4. Dematteis M, Levy P, Pepin JL. A simple procedure for measuring pharyngeal sensitivity: a contribution to the diagnosis of sleep apnoea. Thorax 2005; 60: 418-426.
5. Wellman A, Jordan AS, Malhotra A, et al. Ventilatory control and airway anatomy in obstructive sleep apnea. Am J Respir Crit Care Med 2004; 170: 1225-1232.
6. Redolfi S, Yumino D, Ruttanaumpawan P, et al. Relationship between overnight rostral fluid shift and obstructive sleep apnea in nonobese men. Am J Respir Crit Care Med 2009; 179: 241-246.
7. Chiu KL, Ryan CM, Shiota S, et al. Fluid shift by lower body positive pressure increases pharyngeal resistance in healthy subjects. Am J Respir Crit Care Med 2006; 174: 1378-1383.
8. Gami AS, Howard DE, Olson EJ, et al. Day-night pattern of sudden death in obstructive sleep apnea. N Engl J Med 2005; 352: 1206-1214.
9. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-1053.
10. Arzt M, Young T, Finn L, et al. Association of sleep-disordered breathing and the occurrence of stroke. Am J Respir Crit Care Med 2005; 172: 1447-1451.
11. Mehra R, Benjamin EJ, Shahar E, et al. Association of nocturnal arrhythmias with sleep-disordered breathing: the Sleep Heart Health Study. Am J Respir Crit Care Med 2006; 173: 910-916.
12. Baguet JP, Hammer L, Levy P, et al. Night-time and diastolic hypertension are common and underestimated conditions in newly diagnosed apnoeic patients. J Hypertens 2005; 23: 521-527.
13. Alchanatis M, Tourkohoriti G, Kosmas EN, et al. Evidence for left ventricular dysfunction in patients with obstructive sleep apnoea syndrome. Eur Respir J 2002; 20: 1239-1245.
14. Baguet JP, Barone-Rochette G, Levy P, et al. Left ventricular diastolic dysfunction is linked to severity of obstructive sleep apnoea. Eur Respir J 2010; 36: 1323-1329.
15. Baguet JP, Hammer L, Levy P, et al. The severity of oxygen desaturation is predictive of carotid wall thickening and plaque occurrence. Chest 2005; 128: 3407-3412.
16. Garrigue S, Pepin JL, Defaye P, et al. High prevalence of sleep apnea syndrome in patients with long-term pacing: the European Multicenter Polysomnographic Study. Circulation 2007; 115: 1703-1709.
17. Lavie L. Obstructive sleep apnoea syndrome-an oxidative stress disorder. Sleep Med Rev 2003; 7: 35-51.
18. Lavie L, Vishnevsky A, Lavie P. Evidence for lipid peroxidation in obstructive sleep apnea. Sleep 2004; 27: 123-128.
19. Barcelo A, Miralles C, Barbe F, et al. Abnormal lipid peroxidation in patients with sleep apnoea. Eur Respir J 2000; 16: 644-647.
20. Svatikova A, Wolk R, Lerman LO, et al. Oxidative stress in obstructive sleep apnoea. Eur Heart J 2005; 26: 2435-2439.
21. Barcelo A, Barbe F, de la Pena M, et al. Antioxidant status in patients with sleep apnoea and impact of continuous positive airway pressure treatment. Eur Respir J 2006; 27: 756-760.
22. Ohga E, Tomita T, Wada H, et al. Effects of obstructive sleep apnea on circulating ICAM-1, IL-8, and MCP-1. J Appl Physiol 2003; 94: 179-184.
23. Lavie L, Dyugovskaya L, Lavie P. Sleep-apnea-related intermittent hypoxia and atherogenesis: adhesion molecules and monocytes/endothelial cells interactions. Atherosclerosis 2005; 183: 183-184.
24. Schulz R, Mahmoudi S, Hattar K, et al. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea. Impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 2000; 162: 566-570.
25. Dyugovskaya L, Lavie P, Lavie L Increased adhesion molecules expression, production of reactive oxygen species in leukocytes of sleep apnea patients. Am J Respir Crit Care Med 2002; 165: 934-939.
26. Carpagnano GE, Kharitonov SA, Resta O, et al. Increased 8- isoprostane and interleukin-6 in breath condensate of obstructive sleep apnea patients. Chest 2002; 122: 1162-1167.
27. Minoguchi K, Yokoe T, Tanaka A, et al. Association between lipid peroxidation and inflammation in obstructive sleep apnoea. Eur Respir J 2006; 28: 378-385.
28. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated Creactive protein in patients with obstructive sleep apnea. Circulation 2002; 105: 2462-2464.
29. Dematteis M, Godin-Ribuot D, Arnaud C, et al. Cardiovascular consequences of sleep-disordered breathing: contribution of animal models to understanding the human disease. ILAR 2009; 50: 262-281.
30. Tamisier R, Gilmartin GS, Launois SH, et al. A new model of chronic intermittent hypoxia in humans: effect on ventilation, sleep, and blood pressure. J Appl Physiol 2009; 107: 17-24.
31. Tamisier R, Pépin JL, Rémy J, et al. 14 nights of intermittent hypoxia elevate daytime blood pressure and sympathetic activity in healthy humans. Eur Respir J 2011; 37: 119-128.
32. Phillips B. Your tax dollars at work! Or the APPLES trial bears fruit. J Clin Sleep Med 2008; 4: 419-420.
33. Barbe F, Duran-Cantolla J, Capote F, et al. Long-term effect of continuous positive airway pressure in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 2010; 181: 718-726.
34. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046-1053.
35. Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised parallel trial. Lancet 2002; 359: 204-210.
36. Jenkinson C, Davies RJ, Mullins R, et al. Comparison of therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnoea: a randomised prospective parallel trial. Lancet 1999; 353: 2100-2105.
37. Weaver TE, Maislin G, Dinges DF, et al. Relationship between hours of CPAP use and achieving normal levels of sleepiness and daily functioning. Sleep 2007; 30: 711-719.
38. Pepin JL, Viot-Blanc V, Escourrou P, et al. Prevalence of residual excessive sleepiness in CPAP-treated sleep apnoea patients: the French multicentre study. Eur Respir J 2009; 33: 1062-1067.
39. Pepin JL, Tamisier R, Barone-Rochette G, et al. Comparison of continuous positive airway pressure and valsartan in hypertensive sleep apnea patients. Am J Respir Crit Care Med 2010; 182: 954-960.
40. West SD, Nicoll DJ, Wallace TM, et al. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007; 62: 969-974.
41. Sharma SK, Kumpawat S, Goel A, et al. Obesity, and not obstructive sleep apnea, is responsible for metabolic abnormalities in a cohort with sleep-disordered breathing. Sleep Med 2007; 8: 12-17.
42. Lim J, Lasserson TJ, Fleetham J, et al. Oral appliances for obstructive sleep apnoea. Cochrane Database Syst Rev 2006; 1: CD004435.
43. Gagnadoux F, Fleury B, Vielle B, et al. Titrated mandibular advancement versus positive airway pressure for sleep apnoea. Eur Respir J 2009; 34: 914-920.
44. Johansson K, Neovius M, Lagerros YT, et al. Effect of a very low energy diet on moderate and severe obstructive sleep apnoea in obese men: a randomised controlled trial. BMJ 2009; 339: b4609.
45. Greenburg DL, Lettieri CJ, Eliasson AH. Effects of surgical weight loss on measures of obstructive sleep apnea: a metaanalysis. Am J Med 2009; 122: 535-542.
46. Pepin JL, Ferretti G, Veale D, et al. Somnofluoroscopy, computed tomography, and cephalometry in the assessment of the airway in obstructive sleep apnoea. Thorax 1992; 47: 150-156.
47. Dempsey JA, Veasey SC, Morgan BJ, et al. Pathophysiology of sleep apnea. Physiol Rev 2010; 90: 47-112.
48. Mayer P, Pepin JL, Bettega G, et al. Relationship between body mass index, age and upper airway measurements in snorers and sleep apnoea patients. Eur Respir J 1996; 9: 1801-1809.
49. Schwartz AR, Gold AR, Schubert N, et al. Effect of weight loss on upper airway collapsibility in obstructive sleep apnea. Am Rev Respir Dis 1991; 144: 494-498.
50. Morrell MJ, Arabi Y, Zahn B, et al. Progressive retropalatal narrowing preceding obstructive apnea. Am J Respir Crit Care Med 1998; 158: 1974-1981.
51. Tamisier R, Pepin JL, Wuyam B, et al. Expiratory changes in pressure: flow ratio during sleep in patients with sleepdisordered breathing. Sleep 2004; 27: 240-248.
52. Horner RL. Motor control of the pharyngeal musculature and implications for the pathogenesis of obstructive sleep apnea. Sleep 1996; 19: 827-853.
53. Mezzanotte WS, Tangel DJ, White DP. Waking genioglossal electromyogram in sleep apnea patients versus normal controls (a neuromuscular compensatory mechanism). J Clin Invest 1992; 89: 1571-1579.
54. Berry RB, White DP, Roper J, et al. Awake negative pressure reflex response of the genioglossus in OSA patients and normal subjects. J Appl Physiol 2003; 94: 1875-1882.
55. Carrera M, Barbe F, Sauleda J, et al. Patients with obstructive sleep apnea exhibit genioglossus dysfunction that is normalized after treatment with continuous positive airway pressure. Am J Respir Crit Care Med 1999; 159: 1960-1966.
56. Khoo MC, Kronauer RE, Strohl KP, et al. Factors inducing periodic breathing in humans: a general model. J Appl Physiol 1982; 53: 644-59.
57. Foster GD, Borradaile KE, Sanders MH, et al. A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes: the Sleep AHEAD study. Arch Intern Med 2009; 169: 1619-1626.
58. Peppard PE, Young T, Palta M, et al. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000; 284: 3015-3021.
59. Young T, Peppard PE, Taheri S. Excess weight and sleepdisordered breathing. J Appl Physiol 2005; 99: 1592-1599.
60. Series F, Chakir J, Boivin D. Influence of weight and sleep apnea status on immunologic and structural features of the uvula. Am J Respir Crit Care Med 2004; 170: 1114-1119.
61. Svanborg E. Upper airway nerve lesions in obstructive sleep apnea. Am J Respir Crit Care Med 2001; 164: 187-189.
62. Dematteis M, Pepin JL, Jeanmart M, et al. Charcot-Marie-tooth disease and sleep apnoea syndrome: a family study. Lancet 2001; 357: 267-272.
63. Kimoff RJ, Sforza E, Champagne V, et al. Upper airway sensation in snoring and obstructive sleep apnea. Am J Respir Crit Care Med 2001; 164: 250-255.
64. Jobin V, Champagne V, Beauregard J, et al. Swallowing function and upper airway sensation in obstructive sleep apnea. J Appl Physiol 2007; 102: 1587-1594.
65. Shiota S, Ryan CM, Chiu KL, et al. Alterations in upper airway cross-sectional area in response to lower body positive pressure in healthy subjects. Thorax 2007; 62: 868-872.
66. Su MC, Chiu KL, Ruttanaumpawan P, et al. Lower body positive pressure increases upper airway collapsibility in healthy subjects. Respir Physiol Neurobiol 2008; 161: 306-312.
67. Redolfi S, Arnulf I, Pottier M, et al. Effects of venous compression of the legs on overnight rostral fluid shift and obstructive sleep apnea. Respir Physiol Neurobiol 2011; 175: 390-393.
68. Yumino D, Redolfi S, Ruttanaumpawan P, et al. Nocturnal rostral fluid shift: a unifying concept for the pathogenesis of obstructive and central sleep apnea in men with heart failure. Circulation 2010; 121: 1598-1605.
69. Friedman O, Bradley TD, Chan CT, et al. Relationship between overnight rostral fluid shift and obstructive sleep apnea in drugresistant hypertension. Hypertension 2010; 56: 1077-1082.
70. Garvey JF, Taylor CT, McNicholas WT. Cardiovascular disease in obstructive sleep apnoea syndrome: the role of intermittent hypoxia and inflammation. Eur Respir J 2009; 33: 1195-1205.
71. Nieto FJ, HerringtonDM, Redline S, et al. Sleep apnea andmarkers of vascular endothelial function in a large community sample of older adults. Am J Respir Crit Care Med 2004; 169: 354-360.
72. Itzhaki S, Lavie L, Pillar G, et al. Endothelial dysfunction in obstructive sleep apnea measured by peripheral arterial tone response in the finger to reactive hyperemia. Sleep 2005; 28: 594-600.
73. Borel J-C, Roux-Lombard P, Tamisier R, et al. Endothelial dysfunction and specific inflammation in obesity hypoventilation syndrome. PLoS ONE 2009; 4: e6733.
74. Marin JM, Soriano JB, Carrizo SJ, et al. Outcomes in patients with chronic obstructive pulmonary disease and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 2010; 182: 325-331.
75. Jelic S, Lederer DJ, Adams T, et al. Vascular inflammation in obesity and sleep apnea. Circulation 2010; 121: 1014-1021.
76. Pierce GL, Lesniewski LA, Lawson BR, et al. Nuclear factorkappaB activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/obese middle-aged and older humans. Circulation 2009; 119: 1284-1292.
77. Stanke-Labesque F, Back M, Lefebvre B, et al. Increased urinary leukotriene E4 excretion in obstructive sleep apnea: effects of obesity and hypoxia. J Allergy Clin Immunol 2009; 124: 364-370.
78. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome. Circulation 2005; 112: 2660-2667.
79. Yokoe T, Minoguchi K, Matsuo H, et al. Elevated levels of Creactive protein and interleukin-6 in patients with obstructive sleep apnea syndrome are decreased by nasal continuous positive airway pressure. Circulation 2003; 107: 1129-1134.
80. Larkin EK, Rosen CL, Kirchner HL, et al. Variation of C-reactive protein levels in adolescents: association with sleep-disordered breathing and sleep duration. Circulation 2005; 111: 1978-1984.
81. Lui MM, Lam JC, Mak HK, et al. C-reactive protein is associated with obstructive sleep apnea independent of visceral obesity. Chest 2009; 135: 950-956.
82. Guilleminault C, Kirisoglu C, Ohayon MM. C-reactive protein and sleep-disordered breathing. Sleep 2004; 27: 1507-1511.
83. Kohler M, Ayers L, Pepperell JCT, et al. Effects of continuous positive airway pressure on systemic inflammation in patients with moderate to severe obstructive sleep apnoea: a randomized controlled trial. Thorax 2009; 64: 67-73.
84. Lefebvre B, Pepin JL, Baguet JP, et al. Leukotriene B4: early mediator of atherosclerosis in obstructive sleep apnoea? Eur Respir J 2008; 32: 113-120.
85. Monneret D, Pepin J-L, Godin-Ribuot D, et al. Association of urinary 15-F2t-isoprostane level with oxygen desaturation and carotid intima-media thickness in nonobese sleep apnea patients. Free Radic Biol Med 2010; 48: 619-625.
86. Fletcher EC, Lesske J, Qian W, et al. Repetitive, episodic hypoxia causes diurnal elevation of blood pressure in rats. Hypertension 1992; 19: 555-561.
87. Fletcher EC, Bao G, Li R. Renin activity and blood pressure in response to chronic episodic hypoxia. Hypertension 1999; 34: 309-314.
88. Julien C, Bayat S, Levy P. Vascular reactivity to norepinephrine and acetylcholine after chronic intermittent hypoxia in mice. Respir Physiol Neurobiol 2003; 139: 21-32.
89. Lefebvre B, Godin-Ribuot D, Joyeux-Faure M, et al. Functional assessment of vascular reactivity after chronic intermittent hypoxia in the rat. Respir Physiol Neurobiol 2006; 150: 278-286.
90. Greenberg HE, Sica A, Batson D, et al. Chronic intermittent hypoxia increases sympathetic responsiveness to hypoxia and hypercapnia. J Appl Physiol 1999; 86: 298-305.
91. Brooks D, Horner RL, Floras JS, et al. Baroreflex control of heart rate in a canine model of obstructive sleep apnea. Am J Respir Crit Care Med 1999; 159: 1293-1297.
92. McGuire M, Bradford A. Chronic intermittent hypercapnic hypoxia increases pulmonary arterial pressure and haematocrit in rats. Eur Respir J 2001; 18: 279-285.
93. Kraiczi H, Magga J, Sun XY, et al. Hypoxic pressor response, cardiac size, and natriuretic peptides are modified by long-term intermittent hypoxia. J Appl Physiol 1999; 87: 2025-2031.
94. Phillips SA, Olson EB, Morgan BJ, et al. Chronic intermittent hypoxia impairs endothelium-dependent dilation in rat cerebral and skeletal muscle resistance arteries. Am J Physiol Heart Circ Physiol 2004; 286: H388-H393.
95. Allahdadi KJ, Walker BR, Kanagy NL. Augmented endothelin vasoconstriction in intermittent hypoxia-induced hypertension. Hypertension 2005; 45: 705-709.
96. Belaidi E, Joyeux-Faure M, Ribuot C, et al. Major role for hypoxia inducible factor-1 and the endothelin system in promoting myocardial infarction and hypertension in an animal model of obstructive sleep apnea. J Am Coll Cardiol 2009; 53: 1309-1317.
97. Beguin PC, Joyeux-Faure M, Godin-Ribuot D, et al. Acute intermittent hypoxia improves rat myocardium tolerance to ischemia. J Appl Physiol 2005; 99: 1064-1069.
98. Joyeux-Faure M, Stanke-Labesque F, Lefebvre B, et al. Chronic intermittent hypoxia increases infarction in the isolated rat heart. J Appl Physiol 2005; 98: 1691-1696.
99. Fletcher EC. Effect of episodic hypoxia on sympathetic activity and blood pressure. Respir Physiol 2000; 119: 189-197.
100. Dematteis M, Julien C, Guillermet C, et al. Intermittent hypoxia induces early functional cardiovascular remodeling in mice. Am J Respir Crit Care Med 2008; 177: 227-235.
101. Kanagy NL, Walker BR, Nelin LD. Role of endothelin in intermittent hypoxia-induced hypertension. Hypertension 2001; 37: 511-515.
102. Morgan BJ. Vascular consequences of intermittent hypoxia. Adv Exp Med Biol 2007; 618: 69-84.
103. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695.
104. Foster GE, Poulin MJ, Hanly PJ. Intermittent hypoxia and vascular function: implications for obstructive sleep apnoea. Exp Physiol 2007; 92: 51-65.
105. Greenberg H, Ye X, Wilson D, et al. Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem Biophys Res Commun 2006; 343: 591-596.
106. Ohga E, Nagase T, Tomita T, et al. Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol 1999; 87: 10-14.
107. Nacher M, Serrano-Mollar A, Farre R, et al. Recurrent obstructive apneas trigger early systemic inflammation in a rat model of sleep apnea. Respir Physiol Neurobiol 2007; 155: 93-96.
108. Arnaud C, Beguin P, Lantuejoul S, et al. The inflammatory preatherosclerotic remodeling induced by intermittent hypoxia is attenuated by RANTES/CCL5 inhibition. Am J Respir Crit Care Med 2011 [Epub ahead of print DOI: 10.1164/rccm.201012- 2033OC].
109. Flemons WW, Douglas NJ, Kuna ST, et al. Access to diagnosis and treatment of patients with suspected sleep apnea. Am J Respir Crit Care Med 2004; 169: 668-672
110. Pack AI. Sleep-disordered breathing: access is the issue. Am J Respir Crit Care Med 2004; 169: 666-667.
111. Collop NA, Anderson WM, Boehlecke B, et al. Clinical guidelines for the use of unattended portable monitors in the diagnosis of obstructive sleep apnea in adult patients. Portable Monitoring Task Force of the American Academy of Sleep Medicine. J Clin Sleep Med 2007; 3: 737-747.
112. Flemons WW, Littner MR, Rowley JA, et al. Home diagnosis of sleep apnea: a systematic review of the literature. An evidence review cosponsored by the American Academy of Sleep Medicine, the American College of Chest Physicians, and the American Thoracic Society. Chest 2003; 124: 1543-1579.
113. Kuna ST, Badr MS, Kimoff RJ, et al. An official ATS/AASM/ACCP/ERS workshop report: research priorities in ambulatory management of adults with obstructive sleep apnea. Proc Am Thorac Soc 2011; 8: 1-16.
114. Gozal D, Jortani S, Snow AB, et al. Two-dimensional differential in-gel electrophoresis proteomic approaches reveal urine candidate biomarkers in paediatric obstructive sleep apnea. Am J Respir Crit Care Med 2009; 180: 1253-1261.
115. McNicholas WT, Bonsignore MR, COST action B26 MC. Sleep apnoea as an independent risk factor for cardiovascular disease: current evidence, basic mechanisms and research priorities. Eur Respir J 2007; 29: 156-178.
116. Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med 2009; 6: e1000132.
117. Neubauer JA. Invited review: physiological and pathophysiological responses to intermittent hypoxia. J Appl Physiol 2001; 90: 1593-1599.
118. Levy P, Pepin JL, Arnaud C, et al. Intermittent hypoxia and sleep-disordered breathing: current concepts and perspectives. Eur Respir J 2008; 32: 1082-1095.
119. Baguet JP, Narkiewicz K, Mallion JM. Update on hypertension management: obstructive sleep apnea and hypertension. J Hypertens 2006; 24: 205-208.
120. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
121. Brooks D, Horner RL, Kimoff RJ, et al. Effect of obstructive sleep apnea versus sleep fragmentation on responses to airway occlusion. Am J Respir Crit Care Med 1997; 155: 1609-1617.
122. Becker HF, Jerrentrup A, Ploch T, et al. Effect of nasal continuous positive airway pressure treatment on blood pressure in patients with obstructive sleep apnea. Circulation 2003; 107: 68-73.
123. Haentjens P, Van Meerhaeghe A, Moscariello A, et al. The impact of continuous positive airway pressure on blood pressure in patients with obstructive sleep apnea syndrome: evidence from a meta-analysis of placebo-controlled randomized trials. Arch Intern Med 2007; 167: 757-764.
124. Barbe F, Mayoralas LR, Duran J, et al. Treatment with continuous positive airway pressure is not effective in patients with sleep apnea but no daytime sleepiness: a randomized, controlled trial. Ann Intern Med 2001; 134: 1015-1023.
125. Robinson GV, Smith DM, Langford BA, et al. Continuous positive airway pressure does not reduce blood pressure in nonsleepy hypertensive OSA patients. Eur Respir J 2006; 27: 1229-1235.
126. Pepin J-L, Tamisier R, Barone-Rochette G, et al. Comparison of continuous positive airway pressure and valsartan in hypertensive patients with sleep apnea. Am J Respir Crit Care Med 2010; 182: 954-960.
127. Lévy P, Pepin JL, Arnaud C, et al. Obstructive sleep apnea and atherosclerosis. Prog Cardiovasc Dis 2009; 51: 400-410.
128. Minoguchi K, Yokoe T, Tazaki T, et al. Increased carotid intimamedia thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 2005; 172: 625-630.
129. Drager LF, Bortolotto LA, Lorenzi MC, et al. Early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2005; 172: 613-618.
130. Drager LF, Bortolotto LA, Krieger EM, et al. Additive effects of obstructive sleep apnea and hypertension on early markers of carotid atherosclerosis. Hypertension 2009; 53: 64-69.
131. Drager LF, Bortolotto LA,Maki-Nunes C, et al. The incremental role of obstructive sleep apnoea on markers of atherosclerosis in patients with metabolic syndrome. Atherosclerosis 2010; 208: 490-495.
132. Drager LF, Lopes HF, Maki-Nunes C, et al. The impact of obstructive sleep apnea on metabolic and inflammatory markers in consecutive patients with metabolic syndrome. PLoS One 2010; 5: e12065.
133. Drager LF, Bortolotto LA, Figueiredo AC, et al. Effects of CPAP on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2007; 176: 706-712.
134. Lévy P, Bonsignore MR, Eckel J. Sleep, sleep-disordered breathing and metabolic consequences. Eur Respir J 2009; 34: 243-260.
135. Tasali E, Ip MS. Obstructive sleep apnea and metabolic syndrome: alterations in glucose metabolism and inflammation. Proc Am Thorac Soc 2008; 5: 207-217.
136. Coughlin SR, Mawdsley L, Mugarza JA, et al. Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome. Eur Heart J 2004; 25: 735-741.
137. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769-1778.
138. Sundstrom J, Riserus U, Byberg L, et al. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006; 332: 878-882.
139. Tasali E, Mokhlesi B, Van Cauter E. Obstructive sleep apnea and type 2 diabetes: interacting epidemics. Chest 2008; 133: 496-506.
140. Shaw JE, Punjabi NM, Wilding JP, et al. Sleep-disordered breathing and type 2 diabetes: a report from the International Diabetes Federation Taskforce on Epidemiology and Prevention. Diabetes Res Clin Pract 2008; 81: 2-12.
141. Iiyori N, Alonso LC, Li J, et al. Intermittent hypoxia causes insulin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med 2007; 175: 851-857.
142. Xu J, Long YS, Gozal D, et al. Beta-cell death and proliferation after intermittent hypoxia: role of oxidative stress. Free Radic Biol Med 2009; 46: 783-790.
143. Li J, Thorne LN, Punjabi NM, et al. Intermittent hypoxia induces hyperlipidemia in lean mice. Circ Res 2005; 97: 698-706.
144. Savransky V, Nanayakkara A, Vivero A, et al. Chronic intermittent hypoxia predisposes to liver injury. Hepatology 2007; 45: 1007-1013.
145. Savransky V, Bevans S, Nanayakkara A, et al. Chronic intermittent hypoxia causes hepatitis in a mouse model of diet-induced fatty liver. Am J Physiol Gastrointest Liver Physiol 2007; 293: G871-G877.
146. Tanne F, Gagnadoux F, Chazouilleres O, et al. Chronic liver injury during obstructive sleep apnea. Hepatology 2005; 41: 1290-1296.
147. Aron Wisnewski J, Minville C, Trodjman J, et al. Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. J Hepatology 2011 [Epub ahead of print DOI 10.1016/j.jhep.2011.04.022].
148. West SD, Nicoll DJ, Stradling JR. Prevalence of obstructive sleep apnoea in men with type 2 diabetes. Thorax 2006; 61: 945-950.
149. Harsch IA, Schahin SP, Radespiel-Troger M, et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2004; 169: 156-162.
150. Coughlin SR, Mawdsley L, Mugarza JA, et al. Cardiovascular and metabolic effects of CPAP in obese males with OSA. Eur Respir J 2007; 29: 720-727.
151. West SD, Nicoll DJ, Wallace TM, et al. The effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007; 62: 969-974.
152. Lam JC, Lam B, Yao TJ, et al. A randomised controlled trial of nasal continuous positive airway pressure on insulin sensitivity in obstructive sleep apnoea. Eur Respir J 2010; 35: 138-145.
153. Barcelo A, Barbe F, de la Pena M, et al. Insulin resistance and daytime sleepiness in patients with sleep apnoea. Thorax 2008; 63: 946-950.
154. Young T, Finn L, Peppard PE, et al. Sleep disordered breathing and mortality: eighteen-year follow-up of the Wisconsin sleep cohort. Sleep 2008; 31: 1071-1078.
155. Lévy P, Pépin JL, Tamisier R, et al. Outcomes of OSAand indications for different therapies. Eur Respir Monogr 2010; 50: 225-243.
156. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154-e235.
157. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-2018.
158. Javaheri S, Parker TJ, Liming JD, et al. Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. Circulation 1998; 97: 2154-2159.
159. Tremel F, Pepin JL, Veale D, et al. High prevalence and persistence of sleep apnoea in patients referred for acute left ventricular failure and medically treated over 2 months. Eur Heart J 1999; 20: 1201-1209.
160. Sin DD, Fitzgerald F, Parker JD, et al. Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med 1999; 160: 1101-1106.
161. Bradley TD, Logan AG, Kimoff RJ, et al. Continuous positive airway pressure for central sleep apnea and heart failure. N Engl J Med 2005; 353: 2025-2033.
162. Schulz R, Blau A, Borgel J, et al. Sleep apnoea in heart failure. Eur Respir J 2007; 29: 1201-1205.
163. Oldenburg O, Lamp B, Faber L, et al. Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients. Eur J Heart Fail 2007; 9: 251-257.
164. MacDonald M, Fang J, Pittman SD, et al. The current prevalence of sleep disordered breathing in congestive heart failure patients treated with beta-blockers. J Clin Sleep Med 2008; 4: 38-42.
165. Javaheri S, Caref EB, Chen E, et al. Sleep apnea testing and outcomes in a large cohort of medicare beneficiaries with newly diagnosed heart failure. Am J Respir Crit Care Med 2010; 183: 539-546.
166. Lévy P, Pépin J-L, Tamisier R, et al. Prevalence and impact of central sleep apnea in heart failure. Sleep Med Clin 2007; 2: 615-621.
167. Arzt M, Floras JS, Logan AG, et al. Suppression of central sleep apnea by continuous positive airway pressure and transplantfree survival in heart failure: a post hoc analysis of the Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure Trial (CANPAP). Circulation 2007; 115: 3173-3180.
168. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999; 22: 667-689.
169. Nowbar S, Burkart KM, Gonzales R, et al. Obesity-associated hypoventilation in hospitalised patients: prevalence, effects, and outcome. Am J Med 2004; 116: 1-7.
170. Berg G, Delaive K,Manfreda J, et al. The use of health-care resources in obesity-hypoventilation syndrome. Chest 2001; 120: 377-383.
171. Phipps PR, Starritt E, Caterson I, et al. Association of serum leptin with hypoventilation in human obesity. Thorax 2002; 57: 75-76.
172. Redolfi S, Corda L, La Piana G, et al. Long-term non-invasive ventilation increases chemosensitivity and leptin in obesityhypoventilation syndrome. Respir Med 2007; 101: 1191-1195.
173. Olson AL, Zwillich C. The obesity hypoventilation syndrome. Am J Med 2005; 118: 948-956.
174. Atwood CW. Sleep-related hypoventilation: the evolving role of leptin. Chest. 2005; 128: 1079-1081.
175. Yee BJ, Cheung J, Phipps P, et al. Treatment of obesity hypoventilation syndrome and serum leptin. Respiration 2006; 73: 209-212.
176. Campo A, Fruhbeck G, Zulueta JJ, et al. Hyperleptinemia, respiratory drive and hypercapnic response in obese patients. Eur Respir J 2007; 30: 223-231.
177. Chouri-Pontarollo N, Borel JC, Tamisier R, et al. Impaired objective daytime vigilance in obesity-hypoventilation syndrome: impact of noninvasive ventilation. Chest 2007; 131: 148-155.
178. Bixler EO, Vgontzas AN, Ten Have T, et al. Effects of age on sleep apnea in men: I. Prevalence and severity. Am J Respir Crit Care Med 1998; 157: 144-148.
179. Stoohs RA, Gingold J, Cohrs S, et al. Sleep-disordered breathing and systemic hypertension in the older male. J Am Geriatr Soc 1996; 44: 1295-1300.
180. Young T, Shahar E, Nieto FJ, et al. Predictors of sleep-disordered breathing in community-dwelling adults: the Sleep Heart Health Study. Arch Intern Med 2002; 162: 893-900.
181. Lavie P, Lavie L. Unexpected survival advantage in elderly people with moderate sleep apnoea. J Sleep Res 2009; 18: 397-403.
182. Ancoli-Israel S, Klauber MR, Kripke DF, et al. Sleep apnea in female patients in a nursing home. Increased risk of mortality. Chest 1989; 96: 1054-1058.
183. Campos-Rodriguez F, Martinez-Garcia MA, Durán-Cantolla J, et al. Cardiovascular mortality in females with obstructive sleep apnea. Effect of treatment with continuous positive airway pressure. Am J Respir Crit Care Med 2011; 183: A1056.
184. Gooneratne NS, Richards KC, Joffe M, et al. Sleep disordered breathing with excessive daytime sleepiness is a risk factor for mortality in older adults. Sleep 2011; 34: 435-442.
185. Levy P, Pepin JL, Malauzat D, et al. Is sleep apnea syndrome in the elderly a specific entity? Sleep 1996; 19: Suppl. 3, S29-S38.
186. Parish JM, Lyng PJ, Wisbey J. Compliance with CPAP in elderly patients with OSA. Sleep Med 2000; 1: 209-214.
187. Pelletier-Fleury N, Rakotonanahary D, Fleury B. The age and other factors in the evaluation of compliance with nasal continuous positive airway pressure for obstructive sleep apnea syndrome. A Cox's
188. Russo-Magno P, O'Brien A, Panciera T, et al. Compliance with CPAP therapy in older men with obstructive sleep apnea. J Am Geriatr Soc 2001; 49: 1205-1211.